DexCom, Inc.
NASDAQ:DXCMMedical - Devices
+$0.90 today
- Market cap
- $30.78B
- Beta
- 1.44
- P/E (TTM)
- 29.9
- EPS (TTM)
- $2.42
Volume 4.25M
Average 5.43M
DXCM Common Stock Issued
Cash raised by issuing new shares.
DexCom, Inc.NASDAQ: DXCM
Common Stock Issued · Q2 FY2026 · quarter ended Jun 2026
Common stock issued outflow grows to $0
Q2 FY2026 common stock issued was $0, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $26.6M. Over 3 fiscal years it compounded at +7.7% a year.
Context
- Common stock issued amounted to 0.6% of revenue in FY2025, unchanged from a year earlier.
- Common stock issued increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly common stock issued holds near $0 or moves back toward the trailing-twelve-month quarterly average of $6.65M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 28.1M USD
- Year-over-year change
- -0.4%
- 4-year CAGR
- +8.5%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.1M | -0.4% |
| FY2024 | 2024-12-31 | 28.2M | +6.0% |
| FY2023 | 2023-12-31 | 26.6M | +18.2% |
| FY2022 | 2022-12-31 | 22.5M | +10.8% |
| FY2021 | 2021-12-31 | 20.3M | — |
Common Stock Issued vs competitors
How DXCM compares with its peers on the latest reported figures
- DXCM's LTM Jun 2026 common stock issued of $26.6M is the 3rd largest of the 7 companies compared; the peer median is $13.74M.
- Its year-over-year change of -8.3% is the 2nd highest of 5, against a peer median of -76.4%.
- Common stock issued amounts to 0.5% of revenue for DXCM, versus a peer median of 10.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $538M | — | — | 16.7% |
| LTM Mar 2026 | $77.69M | +73.3% | +43.4% | 190.8% | |
| LTM Jun 2026 | $26.6M | -8.3% | +7.7% | 0.5% | |
| LTM Mar 2026 | $17.37M | — | -14.3% | 82.0% | |
| LTM Jun 2026 | $10.1M | -62.5% | +27.6% | 0.3% | |
| LTM Mar 2026 | $4.38M | -98.4% | +720.5% | 4.0% | |
| LTM Mar 2026 | $662K | -90.4% | — | 0.1% | |
MMEDVMiniMed Group, Inc. | — | — | — | — | — |
| Peer median (excluding DXCM) | $13.74M | -76.4% | +35.5% | 10.3% | |
Competitors are the stored peer set for DXCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 154.7M | 341.2M | 541.5M | 576.2M | 836.3M |
| Depreciation & Amortization | 102M | 155.9M | 186M | 217.7M | 251.8M |
| Deferred Income Tax | (4.9M) | (21.6M) | (55M) | (43.8M) | 182.2M |
| Stock-Based Compensation | 113.4M | 126.5M | 150.8M | 170.4M | 159.6M |
| Change in Working Capital | (132M) | 27.7M | 3.2M | 108.8M | 103.4M |
| Accounts Receivables | (75.5M) | (199.9M) | (260.1M) | (35M) | (201.9M) |
| Inventory | (112.2M) | 49.3M | (252.6M) | 12.4M | (63.7M) |
| Accounts Payables | 58M | 295.1M | 466.5M | 211.7M | 347M |
| Other Working Capital | (2.3M) | (116.8M) | 49.4M | (80.3M) | 22M |
| Other Non-Cash Items | 209.3M | 39.8M | (78M) | (39.8M) | (92.6M) |
| Operating Cash Flow | 442.5M | 669.5M | 748.5M | 989.5M | 1.44B |
| Capital Expenditures | (389.2M) | (364.8M) | (236.6M) | (358.8M) | (363.5M) |
| Acquisitions (Net) | (30.2M) | (3.9M) | 0 | 0 | 0 |
| Purchases of Investments | (2.47B) | (2.27B) | (3.2B) | (2.66B) | (1.27B) |
| Sales of Investments | 2.67B | 2.13B | 2.95B | 2.82B | 2.16B |
| Other Investing Activities | 10.1M | (14.3M) | (17.6M) | (15.5M) | 600K |
| Investing Cash Flow | (216.1M) | (521.5M) | (507.2M) | (207.5M) | 536M |
| Debt Repayment | 0 | 0 | 443.3M | 0 | (1.21B) |
| Common Stock Issued | 20.3M | 22.5M | 26.6M | 28.2M | 28.1M |
| Common Stock Repurchased | 0 | (557.7M) | (688.7M) | (750M) | (500M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.9M) | (17.3M) | (99.8M) | (13M) | (7M) |
| Financing Cash Flow | 10.4M | (552.5M) | (318.6M) | (734.8M) | (1.69B) |
| Effect of Forex Changes | (1.4M) | (5.8M) | 1.5M | (7.4M) | 21.5M |
| Net Change in Cash | 235.4M | (410.3M) | (75.8M) | 39.8M | 311.8M |
| Free Cash Flow | 53.3M | 304.7M | 511.9M | 630.7M | 1.08B |
DexCom, Inc.
NASDAQ:DXCM
Intrinsic Alpha fair value
Locked
Current Price
$82.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.